Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04491006 · ClinicalTrials.gov registry record · Phase 2
A Study of ATH-1017 in Mild to Moderate Alzheimer's Disease
A Phase 2 study, sponsored by LeonaBio.
- Completed
- Registry status
- Phase 2
- Development phase
- 77
- Enrollment target
NCT04491006 is a Phase 2 study that has completed, run by LeonaBio. The registered enrollment target is 77 participants.
The verdict
NCT04491006, a Phase 2 study, has completed, sponsored by LeonaBio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 77 participants
- Enrollment target
Study Summary
This study is designed to evaluate treatment effects of ATH-1017 (fosgonimeton) in mild to moderate Alzheimer's subjects with a randomized treatment duration of 26-weeks.
Interventions
- DRUG Placebo
- DRUG ATH-1017
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2020-11-23 |
| Est. Completion | 2022-05-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04491006
The ClinicalTrials.gov registry entry for NCT04491006 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LeonaBio, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04491006 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04491006 about?
NCT04491006 is a clinical study titled "A Study of ATH-1017 in Mild to Moderate Alzheimer's Disease". This study is designed to evaluate treatment effects of ATH-1017 (fosgonimeton) in mild to moderate Alzheimer's subjects with a randomized treatment duration of 26-weeks.
What is the current status of trial NCT04491006?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2020-11-23. Estimated completion is 2022-05-20.
What interventions are being tested in trial NCT04491006?
The interventions under investigation include: Placebo (DRUG), ATH-1017 (DRUG).
Who is sponsoring clinical trial NCT04491006?
This trial is sponsored by LeonaBio, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.